Back

Presence of NCOR1+/CD4+ T cells in tertiary lymphoid organ predicts favorable prognosis in pancreatic ductal adenocarcinoma

Sheng, W.; Dong, T.; Gao, W.; Yi, T.; Gong, Y.

2023-10-18 cancer biology
10.1101/2023.10.15.562444 bioRxiv
Show abstract

CD4+ T cells have critical roles in anti-tumour immunity and its differentiation is known to be regulated by the nuclear receptor co-repressor 1 (NCOR1). Previous studies suggested that high CD4+ T cells are associated with a favourable prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). However, the prognostic significance of NCOR1 in PDAC is still missing. In this study, the pathological impact of NCOR1 and CD4 has been analysed by multiplex immunohistochemistry in 100 PADC patients. NCOR1 expression in tertiary lymphoid organs is positively associated with the good prognosis of PDAC patients, while its expression in tumour tissue is not. Furthermore, the presence of NCOR1+/CD4+ T cells in tertiary lymphoid organs predicts a favourable prognosis in PDAC. Mechanistically, upregulation of NCOR1 expression in CD4+ T cells increases the release of TNF-, which induces the apoptosis of the tumor cells in vitro. Together, our data highlighted the tumour suppressive role of NCOR1+/CD4+ T cells in PDAC.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Translational Oncology
○ 21 papers in training set
Top 0.1%
17.2%
2
Frontiers in Oncology
○ 103 papers in training set
Top 0.2%
9.9%
3
PLOS ONE
● 5266 papers in training set
Top 31%
4.9%
4
Theranostics
● 37 papers in training set
Top 0.1%
4.4%
5
Cancer Medicine
○ 26 papers in training set
Top 0.2%
4.1%
6
Frontiers in Immunology
○ 638 papers in training set
Top 4%
3.2%
7
Scientific Reports
○ 3612 papers in training set
Top 41%
2.5%
8
eLife
● 5828 papers in training set
Top 41%
2.4%
9
BMC Cancer
○ 67 papers in training set
Top 1.0%
2.1%
50% of probability mass above
10
Cell Death & Disease
○ 126 papers in training set
Top 1%
2.1%
11
Cancers
○ 213 papers in training set
Top 3%
1.8%
12
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.3%
1.8%
13
OncoImmunology
○ 24 papers in training set
Top 0.4%
1.5%
14
Biochemistry and Biophysics Reports
○ 30 papers in training set
Top 0.5%
1.5%
15
Biomedicines
○ 67 papers in training set
Top 1%
1.4%
16
Journal of Translational Medicine
○ 57 papers in training set
Top 1%
1.1%
17
Cancer Letters
○ 35 papers in training set
Top 0.7%
1.1%
18
iScience
○ 1154 papers in training set
Top 24%
1.1%
19
Cancer Immunology, Immunotherapy
○ 12 papers in training set
Top 0.2%
1.1%
20
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 1%
1.1%
21
Journal of Cellular and Molecular Medicine
○ 20 papers in training set
Top 0.5%
1.1%
22
Molecular Therapy - Nucleic Acids
○ 25 papers in training set
Top 0.5%
1.0%
23
International Journal of Molecular Sciences
○ 494 papers in training set
Top 13%
1.0%
24
PeerJ
◐ 308 papers in training set
Top 10%
0.9%
25
International Journal of Cancer
○ 49 papers in training set
Top 1%
0.9%
26
British Journal of Cancer
○ 49 papers in training set
Top 2%
0.9%
27
Cell Death Discovery
○ 58 papers in training set
Top 1%
0.9%
28
Neoplasia
○ 23 papers in training set
Top 0.8%
0.9%
29
Molecular Biology Reports
○ 21 papers in training set
Top 0.9%
0.9%
30
Frontiers in Genetics
○ 230 papers in training set
Top 5%
0.9%